Publications by authors named "F I Al-Jenoobi"
Article Synopsis
- - This study investigates how eugenol affects the activity of four specific liver enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A4) by using human liver microsomes and observing how eugenol inhibits metabolite formation.
- - Eugenol inhibited the activities of CYP1A2 and CYP2C9 significantly more at higher concentrations, with inhibition rates reaching up to about 63% and 67% respectively, while CYP2D6 and CYP3A4 were also affected but to slightly lesser degrees.
- - The findings suggest the potential for herb-drug interactions when eugenol is taken with medications processed by these enzymes, especially CYP2C9, CYP
Pharmacokinetics of Dasatinib in Rats: a Potential Food-Drug Interaction with Naringenin.
Eur J Drug Metab Pharmacokinet
March 2024
Background And Objectives: The novel tyrosine kinase inhibitor (TKI) dasatinib, a multitarget inhibitor of Bcr-Abl and Src family kinases, has been licensed for the treatment of Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia. Many citrus-based foods include the flavonoid naringenin, which is commonly available. Dasatinib is a Cyp3a4, P-gp, and Bcrp1 substrate, which makes it sensitive to potential food-drug interactions.
View Article and Find Full Text PDFMicrowave-Assisted Formation of Ternary Inclusion Complex of Pterostilbene.
Pharmaceuticals (Basel)
November 2023
Pterostilbene (PTS) is a naturally occurring phytoalexin. PTS displays limited water solubility, which consequently results in its diminished oral bioavailability. Therefore, a ternary inclusion complex (TIC) of PTS with β-cyclodextrin (βCD) in the presence of ternary substance Pluronic F-127 (PLF) was prepared using microwave technology.
View Article and Find Full Text PDFSinapic acid (SA) is a bioactive phenolic acid; its diverse properties are its anti-inflammatory, antioxidant, anticancer, and antibacterial activities. The bioactive compound SA is poorly soluble in water. Our goal was to formulate SA-transethosomes using thin-film hydration.
View Article and Find Full Text PDFDasatinib (DAS) is a narrow therapeutic index drug and novel oral multitarget inhibitor of tyrosine kinase and approved for the first-line therapy for chronic myelogenous leukemia (CML) and Philadelphia chromosome (Ph + ) acute lymphoblastic leukemia (ALL). DAS, a known potent substrate of cytochrome (CYP) 3A, P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) and is subject to auto-induction. The dietary supplementation of sinapic acid (SA) or concomitant use of SA containing herbs/foods may alter the pharmacokinetics as well as pharmacodynamics of DAS, that may probably lead to potential interactions.
View Article and Find Full Text PDF